Toggle menu

PREFER

Start date:
Historic
End date:
June 2014
Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich

Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism

 

Aim

To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE

Trial Design

Multi –national, multi-centre, prospective observational disease registry

Chief Investigator

Dr Petra Laeis, Munich

Local PI

Dr. Matt Reed

Local PI

Dr Matt Reed

Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

More EMERGE Trials

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA

Evaluating the role of early CT Coronary Angiography